Shares of pSivida Corp. (NASDAQ:PSDV) traded up 5.4% during trading on Tuesday . The stock traded as high as $3.18 and last traded at $3.11, with a volume of 64,388 shares. The stock had previously closed at $2.95.

Separately, FBR & Co reiterated a “buy” rating and issued a $7.00 price target (up previously from $6.00) on shares of pSivida Corp. in a research note on Thursday, May 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $6.75.

The firm has a 50 day moving average price of $3.17 and a 200-day moving average price of $3.19. The firm’s market cap is $103.20 million.

pSivida Corp. (NASDAQ:PSDV) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.05. Analysts anticipate that pSivida Corp. will post ($0.62) earnings per share for the current year.

pSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company’s lead development product, Medidur is used for posterior of the eye (posterior uveitis).